SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”) will be used for screening all attendees of the upcoming 59th World Boxing Council Annual Convention in Mexico City, Mexico (November 14th through November 18th).
Related Articles

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment. This study is a multi-center, double blind, placebo- and active-controlled study to assess the safety… Click here to view original post… […]

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that it will participate in the Cantor Virtual Healthcare Conference. Click here to view original post… […]

Sorrento Therapeutics Announces $25 Million Registered Direct Offering
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable … […]